Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms
| Status: | Completed |
|---|---|
| Conditions: | Smoking Cessation |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/2/2016 |
| Start Date: | October 2010 |
| End Date: | June 2014 |
| Contact: | Laura MacPherson, PhD |
| Email: | umdquit@gmail.com |
| Phone: | 301-405-4188 |
Stage II Trial of Novel Behavioral Activation Intervention for Smoking Cessation
Depression related vulnerabilities are highly comorbid with smoking behavior and
dramatically reduce cessation rates among both community and clinical samples. Previous
research has examined the efficacy of cognitive-behavioral treatment for individuals with a
history of major depressive disorder (MDD) in standard cessation treatment. A broader health
impact can be achieved by targeting individuals with current elevated depressive symptoms to
address their association with cessation failure. Thus the objective of the present proposal
is to conduct a Stage II randomized controlled trial (RCT) comparing the behavioral
activation intervention to standard treatment among a similar community sample of 200 adult
smokers with elevated depressive symptoms. Participants will be followed over 52 weeks
post-quit date and the larger sample size will allow for more complex analysis of cessation
outcomes.
dramatically reduce cessation rates among both community and clinical samples. Previous
research has examined the efficacy of cognitive-behavioral treatment for individuals with a
history of major depressive disorder (MDD) in standard cessation treatment. A broader health
impact can be achieved by targeting individuals with current elevated depressive symptoms to
address their association with cessation failure. Thus the objective of the present proposal
is to conduct a Stage II randomized controlled trial (RCT) comparing the behavioral
activation intervention to standard treatment among a similar community sample of 200 adult
smokers with elevated depressive symptoms. Participants will be followed over 52 weeks
post-quit date and the larger sample size will allow for more complex analysis of cessation
outcomes.
This will be a Stage II randomized control trial to examine the efficacy of behavioral
activation treatment for smoking (BATS) vs. standard smoking cessation treatment (ST). We
will recruit 200 smokers with elevated depressive symptoms who will be randomized into one
of two treatment groups. Treatment will be delivered in group format across both the BATS (n
= 100) and ST condition (n = 100). All participants will receive 8 weeks of transdermal
nicotine patch in addition to their assigned treatment group. We intend to compare the BA
treatment for smoking (BATS) to a standard smoking cessation intervention (ST)on abstinence
and relapse outcomes. In addition we will examine to what extent depressive symptoms and
reward sensitivity prior to quit date will mediate the effects of BATS on improved smoking
cessation outcomes relative to ST.
activation treatment for smoking (BATS) vs. standard smoking cessation treatment (ST). We
will recruit 200 smokers with elevated depressive symptoms who will be randomized into one
of two treatment groups. Treatment will be delivered in group format across both the BATS (n
= 100) and ST condition (n = 100). All participants will receive 8 weeks of transdermal
nicotine patch in addition to their assigned treatment group. We intend to compare the BA
treatment for smoking (BATS) to a standard smoking cessation intervention (ST)on abstinence
and relapse outcomes. In addition we will examine to what extent depressive symptoms and
reward sensitivity prior to quit date will mediate the effects of BATS on improved smoking
cessation outcomes relative to ST.
Inclusion Criteria:
- Between 18 and 65 years of age
- A regular smoker for at least one year
- Currently smoking an average of at least 10 cigarettes per day
- Want to quit smoking
- Report current elevated depressive symptoms
Exclusion Criteria:
- Current Axis I disorder
- Psychoactive substance dependence (excluding nicotine dependence) within the past 6
months
- Current use of psychotropic medication or participation in any form of psychotherapy
- A history of significant medical condition (e.g., cardiovascular , neurological,
gastrointestinal), pregnancy and/or breast feeding, or other systemic illness
- Current use of any pharmacotherapy for smoking cessation not provided by the
researchers during the quit attempt
We found this trial at
1
site
Click here to add this to my saved trials
